Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

HALIFAX, Nova Scotia, February 8, 2023– Appili Therapeutics Inc. (TSX: APLI (the“Company” or“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news